Discover and read the best of Twitter Threads about #mesothelioma
Most recents (2)
Some great abstracts in #mesothelioma @AACR2023.
1) Response to CART #meso associated with density of infiltrative TILs with PDL1 and TIGIT as potential targets of resistance. Explains what we see with better outcomes for CART-meso followed by anti-PD1? aacrjournals.org/cancerres/arti…
1) Response to CART #meso associated with density of infiltrative TILs with PDL1 and TIGIT as potential targets of resistance. Explains what we see with better outcomes for CART-meso followed by anti-PD1? aacrjournals.org/cancerres/arti…
2) Data on TEAD inhibitors in #meso. No MTD reached. Response does not correlate with NF2 mutation status. Will need to confirm with larger n. @IbiayiMD @curemeso
aacrjournals.org/cancerres/arti…
aacrjournals.org/cancerres/arti…
3) Building on observation 👆that PD1 May be resistance mech to CARTmeso.
BZDS1901 adds PD1 nanobody. 11 MPM pts: 1 CR, 6 PR, 4 SD. Longest PFS 26 mo. @curemeso
aacrjournals.org/cancerres/arti…
BZDS1901 adds PD1 nanobody. 11 MPM pts: 1 CR, 6 PR, 4 SD. Longest PFS 26 mo. @curemeso
aacrjournals.org/cancerres/arti…
#ESMO19 Phase 3 ETOP 9-15 trial of pembrolizumab vs chemo (gem/vinorelbine) in previously treated #mesothelioma presented by @DrSanjayPopat - recall RR 20% (5/25) in KN-028 #OncoAlert 
#ESMO19 Primary endpoint was PFS. This study did not meet its primary endpoint. PFS and OS curves overlap. RR higher with pembro but DOR poor. High crossover rates. No clear subgroup that benefits. #OncoAlert
#ESMO19 With pembrolizumab in mesothelioma, no PFS/OS benefit of 2+L pembrolizumab over chemo and PDL1 not discriminating. With monotherapy, need good biomarker and PDL1 not enough. Next step? CPS? Chemo combo? #OncoAlert
